No additional AE/PQC.; Pharmacy student called and reported an adult patient who received two doses of GARDASIL 9 in 2018 and received a third dose of GARDASIL 9 in 2024.; This spontaneous report was received from a pharmacy student and refers to a 26-year-old adult patient with unknown gender. The patient’s medical history was not reported. The patient’s concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown dates in 2018, the patient received first dose and second dose (two doses) of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strengths, doses, lots #, expiry dates, and routes of administration were not provided). On an unknown date in 2024, the patient received a third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided) (Inappropriate schedule of product administration). No additional information was known by reporter. No additional adverse event (AE) (No adverse event). Lots is being requested and will be submitted if received.